1-3 of 3
Anthony L. Boral
Close
Sort by
Journal Articles

Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis

Philina Lee, PhD, Tracy I. George, MD, Hongliang Shi, MS, Erica K. Evans, PhD, Teghpal Singh, PhD, Anthony L Boral, MD PhD, Vanessa Rangel Miller, MS, MBA, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4783.
https://doi.org/10.1182/blood.V128.22.4783.4783
Published: 2016
Journal Articles

Ceritinib in patients with advanced anaplastic lymphoma kinase–rearranged anaplastic large-cell lymphoma

Clinical Trials & Observations
Heike Richly, Tae Min Kim, Martin Schuler, Dong-Wan Kim, Simon J. Harrison, Alice T. Shaw, Anthony L. Boral, Alejandro Yovine, Benjamin Solomon
Journal: Blood
Blood (2015) 126 (10): 1257–1258.
https://doi.org/10.1182/blood-2014-12-617779
Published: 2015
Journal Articles

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

John Gerecitano, MD, PhD, Carol Portlock, MD, Ariela Noy, MD, Paul Hamlin, MD, Craig Moskowitz, MD, David Straus, MD, Steven M. Horwitz, MD, Maria Lia Palomba, MD, Otilia-Liana Dumitrescu, MD, Jennifer Pappanicholaou, Ellen Neylon, Rachel Hamelers, Andrew Zelenetz, MD,PhD, Thomas J. Myers, MD, Anthony L. Boral, MD, Owen A. O’Connor, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 2759.
https://doi.org/10.1182/blood.V108.11.2759.2759
Published: 2006